The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

The FDA is reviewing risperidone (Uzedy) extended-release injectable suspension for maintenance treatment of adults with ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Success of the operation with €42.9 million raised. Participation of US and European Healthcare specialist investors, as well as historical shareholders, in the transaction. Funds raised will ...

MARKHAM, Ontario, Feb. 14, 2025 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share ...